美国多中心炎症性肠病患者队列中脊柱关节炎症状的患病率与危险因素
在美国6家学术医疗中心对无脊柱关节炎(SpA)诊断的炎症性肠病(IBD)患者实施DETAIL和IBIS-Q两种SpA筛查问卷,588例完成筛查,DETAIL阳性130例(22%)、IBIS-Q阳性196例(33%)、任一阳性204例(35%);多因素分析显示女性、年龄较大、吸烟史及任何生物制剂或靶向小分子药物暴露史与筛查阳性独立相关。
要点
- 588例IBD患者中SpA筛查任一问卷阳性204例(35%),提示未诊断SpA症状负担较高。
- 女性(OR 2.03)、年龄较大(OR 1.02)、吸烟史(OR 1.67)、生物制剂或靶向小分子暴露(OR 2.27)与筛查阳性独立相关。
- 生物制剂暴露次数越多筛查阳性风险越高,≥3次暴露OR 3.25(95%CI 1.75-6.03)。
核心结论
- 相当数量IBD患者SpA症状筛查阳性,提示未诊断疾病负担可能较高;与SpA症状相关的因素包括年龄较大、女性及更严重疾病(基于更多先进治疗或既往手术),而IBD表型不独立增加筛查阳性风险。
- 需进一步研究确认这些发现并更好地描述IBD中的SpA。
研究设计与样本
- 在美国6家学术医疗中心对无既往SpA诊断的IBD患者实施两种经验证的SpA筛查问卷(DETAIL和IBIS-Q),并记录人口学、IBD特征及用药史。
- 共588例患者完成筛查问卷:溃疡性结肠炎220例、克罗恩病349例、IBD未分型19例;中位年龄40岁(四分位距30-53),中位病程12年(四分位距6-22)。
主要发现
- 筛查阳性例数:DETAIL 130例(22%),IBIS-Q 196例(33%),DETAIL或IBIS-Q任一阳性204例(35%)。
- 单因素分析中,年龄、女性、吸烟史、既往肠道手术及任何生物制剂或靶向小分子药物暴露史与筛查阳性相关。
- 多因素分析中,女性(OR 2.03,95%CI 1.41-2.93)、年龄较大(OR 1.02,95%CI 1.01-1.04)、吸烟史(OR 1.67,95%CI 1.04-2.69)及任何生物制剂或靶向小分子药物暴露史(OR 2.27,95%CI 1.34-3.84)与筛查阳性独立相关。
- 生物制剂暴露次数越多筛查阳性风险越高,≥3次暴露风险最高(OR 3.25,95%CI 1.75-6.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确认这些发现并更好地描述IBD中的SpA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Spondyloarthritis (SpA), the most common extraintestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% of patients with IBD. Despite this high prevalence, risk factors of developing SpA in patients with IBD are not well described. In this study, we aimed to determine the factors associated with SpA symptoms and their prevalence in an IBD cohort. METHODS: Two validated screening questionnaires for the detection of SpA in IBD (DETAIL = DETection of Arthritis in Inflammatory boweL diseases, IBIS-Q = IBD Identification of Spondyloarthritis Questionnaire) were administered to patients with IBD without a prior diagnosis of SpA in 6 US academic medical centers. Demographic data, IBD characteristics, and medication history were recorded. RESULTS: Screening questionnaires were completed by 588 patients (220 ulcerative colitis, 349 Crohn's disease, and 19 IBD-unclassified), with a median age of 40 years (interquartile range 30-53) and median disease duration of 12 years (interquartile range 6-22). The number of positive screens was 130 (22%) for DETAIL, 196 (33%) for IBIS-Q, and 204 (35%) for either DETAIL or IBIS-Q. Age, female sex, history of smoking, prior bowel surgery, and history of any biologic or targeted small molecule exposure were associated with a positive screen on univariate analysis. After multivariate analysis, female sex (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.41-2.93), older age (OR 1.02, 95% CI 1.01-1.04), history of smoking (OR 1.67, 95% CI 1.04-2.69), and history of any biologic or targeted small molecule exposure (OR 2.27, 95% CI 1.34-3.84) were independently associated with positive screens. Higher number of biologic exposures was associated with higher risk of positive screens, with the highest risk seen with 3 or more exposures (OR 3.25, 95% CI 1.75-6.03). DISCUSSION: A substantial number of patients with IBD screen positive for SpA symptoms, indicating a potentially high burden of undiagnosed illness. Factors associated with SpA symptoms include older age, female sex, and more severe disease (based on increased number of advanced therapies or prior surgery), whereas IBD phenotype does not independently increase the risk of a positive SpA screen. Further studies are needed to confirm these findings and better characterize SpA in IBD.
引用
- Hong SJ, Dalal RS, Kuhn KA, et al. Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2025. PMID: 39760386. doi:10.14309/ajg.0000000000003292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。